Novartis Can't Nix Gleevec Antitrust Suit, Buyers Say
A proposed putative class of purchasers pushed back Thursday against arguments by Novartis Pharmaceuticals Corp. that they lack standing to challenge the validity of leukemia drug Gleevec's patent, claiming their focus...To view the full article, register now.
Already a subscriber? Click here to view full article